文献速递血栓与止血

重组凝血因子VIII产品中无法结合血管性血友病因子的蛋白组分特征分析

Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products.
PubMed 文献 · J Thromb Haemost · 2021-02-24

该研究采用固定化血管性血友病因子亲和层析(IVAC)从美国上市的10种重组凝血因子VIII(rFVIII)产品中分离无法结合血管性血友病因子的组分(FVIIIFT),发现该组分在所有产品中含量为0.4%-21.5%,功能活性较低,且Tyr1680硫酸化降低、与低密度脂蛋白受体相关蛋白1片段相互作用减弱、小鼠体内血浆清除加快。

要点

  • rFVIII产品中普遍存在无法结合血管性血友病因子的FVIIIFT组分,含量0.4%-21.5%。
  • FVIIIFT功能活性较低,Tyr1680硫酸化降低,与LRP1片段相互作用减弱。
  • FVIIIFT在小鼠体内血浆清除更快,IVAC可用于控制该杂质。

核心结论

  • rFVIII产品中FVIIIFT是一种产品相关杂质,具有较低功能活性和较快血浆清除。

研究设计与样本

  • 研究采用固定化血管性血友病因子亲和层析(IVAC)从美国上市的10种重组凝血因子VIII产品中分离FVIIIFT和FVIIIEL,并通过凝胶电泳、免疫印迹、FVIII活性检测、表面等离子共振、质谱及小鼠血浆清除实验进行表征。

主要发现

  • FVIIIFT在所有10种rFVIII产品中均有发现,含量范围为0.4%-21.5%。
  • 与FVIIIEL相比,FVIIIFT经凝胶电泳显示多肽条带模式相似,但功能活性较低。
  • 在几种代表性产品中,FVIIIFT的Tyr1680硫酸化降低,与低密度脂蛋白受体相关蛋白1片段的相互作用减弱,且在小鼠体内血浆清除更快。

临床怎么用

  • IVAC方法可用于控制rFVIII产品中的FVIIIFT杂质,有望提高血友病A治疗的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic products with coagulation factor VIII (FVIII) have a wide range of specific activities, implying presence of protein with altered structure. Previous studies showed that recombinant FVIII products (rFVIII) contain a fraction (FVIIIFT ) unable to bind von Willebrand factor (VWF) and reported to lack activity. Because of loss of function(s), FVIIIFT can be defined as a product-related impurity, whose properties and levels in rFVIII products should be investigated. OBJECTIVE: To isolate and characterize the FVIIIFT fraction in rFVIII products. METHODS: Protein fractions unable (FVIIIFT ) and able (FVIIIEL ) to bind VWF were isolated from rFVIII products using immobilized VWF affinity chromatography (IVAC) and characterized by gel electrophoresis, immunoblotting, FVIII activity test, surface plasmon resonance, mass spectrometry, and for plasma clearance in mice. RESULTS AND CONCLUSIONS: A robust IVAC methodology was developed and applied for analysis of 10 rFVIII products marketed in the United States. FVIIIFT was found at various contents (0.4%-21.5%) in all products. Compared with FVIIIEL , FVIIIFT had similar patterns of polypeptide bands by gel electrophoresis, but lower functional activity. In several representative products, FVIIIFT was found to have reduced sulfation at Tyr1680, important for VWF binding, decreased interaction with a low-density lipoprotein receptor-related protein 1 fragment, and faster plasma clearance in mice. These findings provide basic characterization of FVIIIFT and demonstrate a potential for IVAC to control this impurity in rFVIII products to improve their efficacy in therapy of hemophilia A.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chun H, Pettersson JR, Shestopal SA, et al. Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products. J Thromb Haemost. 2021. PMID: 33527662. doi:10.1111/jth.15257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。